Serum Apolipoprotein A-I is a Novel Prognostic Indicator for Non-Metastatic Nasopharyngeal Carcinoma.

Xiao-Lin Luo,Guang-Zheng Zhong,Li-Yang Hu,Jie Chen,Ying Liang,Qiu-Yan Chen,Qing Liu,Hui-Lan Rao,Kai-Lin Chen,Qing-Qing Cai
DOI: https://doi.org/10.18632/oncotarget.5823
2015-01-01
Oncotarget
Abstract:BACKGROUND:We investigated the value of pretreatment serum apolipoprotein A-I (ApoA-I) in complementing TNM staging in the prognosis of non-metastatic nasopharyngeal carcinoma (NPC).PATIENTS AND METHODS:We retrospectively reviewed 1196 newly diagnosed patients with non-metastatic NPC. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to serum ApoA-I level. Multivariate analysis was performed to assess the prognostic value of serum ApoA-I.RESULTS:The 5-year DSS, DMFS, and LRFS rates for patients with elevated or decreased serum ApoA-I were 81.3% versus 69.3% (P < 0.001), 83.4% versus 67.4% (P < 0.001), and 80.9% versus 67.3% (P < 0.001), respectively. ApoA-I ≥ 1.025 g/L was an independent prognostic factor for superior DSS, DMFS, and LRFS in multivariate analysis. After stratification by clinical stage, serum ApoA-I remained a clinically and statistically significant predictor of prognosis.CONCLUSION:Our data suggest that the level of ApoA-I at diagnosis is a novel independent prognostic marker that could complement clinical staging for risk definition in non-metastatic NPC.
What problem does this paper attempt to address?